Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12874529 | 0.89 | PLAU (0.48) | SCN9AEGLN1ROCK2ROCK1MRGPRX4 | |
| SCHEMBL9909283 | 0.79 | PLAU (0.49) | SCN9AEGLN1MRGPRX4HTR5APLAU | |
| SCHEMBL9909208 | 0.77 | SCN9A (0.51) | SCN9AEGLN1MRGPRX4 | |
| SCHEMBL16509518 | 0.76 | CYP11B1 (0.43) | SCN9AEGLN1ROCK2ROCK1MRGPRX4 | |
| SCHEMBL9909274 | 0.76 | HTR5A (0.47) | HTR5A | |
| SCHEMBL9909169 | 0.76 | PDE5A (0.45) | SCN9AEGLN1ROCK2ROCK1MRGPRX4 | |
| SCHEMBL9909294 | 0.75 | HTR5A (0.59) | HTR5APLAU | |
| SCHEMBL9909289 | 0.74 | MEN1 (0.45) | SCN9AROCK2ROCK1HTR5APLAU | |
| SCHEMBL9909277 | 0.74 | SCN9A (0.50) | SCN9AHTR5A | |
| SCHEMBL16502433 | 0.74 | PLAU (0.49) | SCN9AEGLN1ROCK2ROCK1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SCN9A 412/4885EGLN1 4544/4885ROCK2 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.